We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
(+18%)
Cap. Flow
+$342M
Cap. Flow
% of AUM
9.57%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33
Avg Time Held Equity + Options
4.4
quarters
Top 10 Avg Time Held Equity + Options
5.6
quarters
Top 20 Avg Time Held Equity + Options
4.8
quarters
Avg Time Held Equity only
4.7
quarters
Top 10 Avg Time Held Equity only
5.6
quarters
Top 20 Avg Time Held Equity only
4.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$104M |
| 2 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$79.7M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$55.2M |
| 4 |
YARW
Yarrow Bioscience
YARW
|
+$54M |
| 5 |
Amicus Therapeutics
FOLD
|
+$32.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$58.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$32.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$25.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$24.2M |
| 5 |
Zimmer Biomet
ZBH
|
+$24.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.46% |
| 2 | Miscellaneous | 1.79% |
| 3 | Consumer Staples | 0.67% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Neurocrine Biosciences
NBIX
$13.8B
| $395M | 11.06% |
4,761,989
-389,600
| -8% | -$32.9M |
2013 Q2
19 quarters
|
|
|
2
DELISTED
Amicus Therapeutics
FOLD
| $301M | 8.44% |
20,024,424
+2,135,827
| +12% | +$32.5M |
2014 Q1
16 quarters
|
|
|
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $241M | 6.75% |
4,989,066
+100,000
| +2% | +$5.58M |
2015 Q3
10 quarters
|
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $159M | 4.45% |
3,970,357
| – | – |
2016 Q3
6 quarters
|
|
5
Alnylam Pharmaceuticals
ALNY
$29.8B
| $153M | 4.27% |
1,280,802
-50,000
| -4% | -$6.45M |
2016 Q4
5 quarters
|
|
|
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $128M | 3.6% |
4,313,611
+925,000
| +27% | +$29.8M |
2014 Q3
14 quarters
|
|
7
Iovance Biotherapeutics
IOVA
$6.65B
| $104M | 2.92% |
6,162,202
+1,386,088
| +29% | +$21M |
2015 Q1
12 quarters
|
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
| $97.4M | 2.73% |
+873,450
| New | +$104M |
2018 Q1
0 quarters
|
|
|
ABMD
9
DELISTED
Abiomed Inc
ABMD
| $96.7M | 2.71% |
332,449
+117,449
| +55% | +$29.8M |
2017 Q3
2 quarters
|
|
10
DELISTED
Blueprint Medicines
BPMC
| $94.5M | 2.65% |
1,030,434
-110,000
| -10% | -$9.48M |
2015 Q2
11 quarters
|
|
|
DOVA
11
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $75.4M | 2.11% |
2,780,977
+971,962
| +54% | +$29.1M |
2017 Q2
3 quarters
|
|
|
CORI
12
DELISTED
Corium International, Inc.
CORI
| $72.9M | 2.04% |
6,357,133
+510,000
| +9% | +$6.15M |
2017 Q1
4 quarters
|
|
13
Travere Therapeutics
TVTX
$4.94B
| $71.8M | 2.01% |
3,212,871
+540,346
| +20% | +$12.9M |
2014 Q1
16 quarters
|
|
|
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $71.2M | 1.99% |
2,927,449
+2,666,315
| +1,021% | +$79.7M |
2017 Q2
3 quarters
|
|
|
15
Ascendis Pharma A/S
ASND
$14.8B
| $64.3M | 1.8% |
+982,647
| New | +$55.2M |
2018 Q1
0 quarters
|
|
16
CytomX Therapeutics
CTMX
$527M
| $62.8M | 1.76% |
2,208,812
-281,569
| -11% | -$8.04M |
2016 Q4
5 quarters
|
|
|
YARW
17
Yarrow Bioscience
YARW
$162M
| $60.1M | 1.68% |
+444
| New | +$54M |
2018 Q1
0 quarters
|
|
|
XLRN
18
DELISTED
Acceleron Pharma
XLRN
| $59.3M | 1.66% |
1,516,259
-100,000
| -6% | -$4.25M |
2014 Q2
15 quarters
|
|
|
ALBO
19
DELISTED
Albireo Pharma Inc
ALBO
| $55.5M | 1.55% |
1,704,330
+384,330
| +29% | +$12.9M |
2017 Q2
3 quarters
|
|
20
DBV Technologies S.A. American Depositary Shares
DBVT
$575M
| $48.3M | 1.35% |
209,350
+111,488
| +114% | +$26.3M |
2015 Q2
11 quarters
|
|
21
Merit Medical Systems
MMSI
$5.28B
| $47.4M | 1.33% |
1,045,013
+171,000
| +20% | +$7.74M |
2017 Q3
2 quarters
|
|
22
argenx
ARGX
$50.6B
| $43.2M | 1.21% |
537,361
| – | – |
2017 Q2
3 quarters
|
|
|
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $40.7M | 1.14% |
834,679
+123,953
| +17% | +$6.44M |
2015 Q4
9 quarters
|
|
24
Xencor
XNCR
$1.84B
| $39.5M | 1.11% |
1,318,095
+5,000
| +0.4% | +$131K |
2013 Q4
17 quarters
|
|
|
AVXS
25
DELISTED
AveXis, Inc. Common Stock
AVXS
| $34.2M | 0.96% |
276,400
-203,741
| -42% | -$24.2M |
2016 Q1
8 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2018 Portfolio in Review
As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors deployed $342M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.
- Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
- Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
- Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
- Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
- Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
- Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
- Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.
Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.